インビトロ毒物検査の世界市場予測（～2022年）...市場調査レポートについてご紹介

TABLE OF CONTENTS

1 INTRODUCTION 17
1.1 OBJECTIVES OF THE STUDY 17
1.2 MARKET DEFINITION 17
1.3 MARKET SCOPE 18
1.3.1 MARKETS COVERED 18
1.3.2 YEARS COVERED FOR THE STUDY 18
1.4 CURRENCY 19
1.5 LIMITATIONS 19
1.6 STAKEHOLDERS 19
2 RESEARCH METHODOLOGY 20
2.1 RESEARCH DATA 20
2.2 MARKET SHARE ESTIMATION 22
2.2.1 SECONDARY DATA 22
2.2.1.1 Key data from secondary sources 22
2.2.2 PRIMARY DATA 23
2.2.2.1 Key data from primary sources 23
2.2.2.2 Key industry insights 24
2.3 MARKET SIZE ESTIMATION 25
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 27
2.5 ASSUMPTIONS FOR THE STUDY 28
3 EXECUTIVE SUMMARY 29
4 PREMIUM INSIGHTS 35
4.1 GLOBAL IN VITRO TOXICOLOGY TESTING MARKET OVERVIEW 35
4.2 EUROPE IN VITRO TOXICOLOGY TESTING MARKET: BY TECHNOLOGY & COUNTRY 36
4.3 IN VITRO TOXICOLOGY TESTING MARKET: BY COUNTRY/REGION 37
4.4 IN VITRO TOXICOLOGY TESTING MARKET: GEOGRAPHIC MIX 38
4.5 IN VITRO TOXICOLOGY TESTING MARKET: DEVELOPING VS. DEVELOPED MARKETS
(USD BILLION) 39
5 INDUSTRY INSIGHTS 40
5.1 INTRODUCTION 40
5.2 SUPPLY CHAIN ANALYSIS 40
5.3 REGULATORY COMMITTEE ACTIVITIES 41
5.3.1 MAJOR STAKEHOLDERS 42
5.3.2 KEY INFLUENCERS 42
 
5.4 INDUSTRY TRENDS 43
5.4.1 INCREASING R&D SPENDING IN THE PHARMACEUTICAL AND BIOTECHNOLOGY SECTOR 43
5.4.2 NEW AND PROMISING TECHNOLOGICAL ADVANCEMENTS A KEY AREA OF FOCUS FOR MARKET PLAYERS 44
6 MARKET OVERVIEW 45
6.1 INTRODUCTION 45
6.2 MARKET DYNAMICS 46
6.2.1 DRIVERS 47
6.2.1.1 Opposition to animal testing 47
6.2.1.2 New and promising in vitro technologies 48
6.2.1.3 Increasing R&D expenditure to detect toxicity at an early stage 48
6.2.2 RESTRAINTS 49
6.2.2.1 Reluctance of regulatory authorities to consider alternative methods for proving safety and efficacy 49
6.2.2.2 Failure to establish intricacies of in vivo conditions through in vitro 49
6.2.2.3 Lack of in vitro models to study complex endpoints 49
6.2.3 OPPORTUNITIES 50
6.2.3.1 Toxicology in the 21st century (Tox21) program 50
6.2.3.2 Increasing drug discovery and innovation & modernization in the in vitro toxicity testing market 50
6.2.3.3 Increasing toxicology databases will facilitate the use of in vitro test methods 51
6.2.4 CHALLENGES 51
6.2.4.1 Dearth of skilled professionals 51
7 IN VITRO TOXICOLOGY TESTING MARKET, BY PRODUCT AND SERVICE 52
7.1 INTRODUCTION 53
7.2 ASSAYS 54
7.2.1 BACTERIAL TOXICITY ASSAYS 56
7.2.2 ENZYME TOXICITY ASSAYS 58
7.2.3 CELL-BASED ELISA AND WESTERN BLOTS 60
7.2.4 RECEPTOR-BINDING ASSAYS 62
7.2.5 TISSUE CULTURE ASSAYS 63
7.2.6 OTHER ASSAYS 65
7.3 SERVICES 67
7.4 REAGENTS & LABWARE 69
8 IN VITRO TOXICOLOGY TESTING MARKET, BY TOXICITY ENDPOINTS AND TESTS 71
8.1 INTRODUCTION 72
8.1.1 ADME (ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION) 73
8.1.2 SKIN IRRITATION, CORROSION, AND SENSITIZATION 75
8.1.3 GENOTOXICITY TESTING 77
8.1.4 CYTOTOXICITY TESTING 79
8.1.5 OCULAR TOXICITY 81
8.1.6 ORGAN TOXICITY 83
8.1.7 PHOTOTOXICITY TESTING 84
8.1.8 DERMAL TOXICITY 86
8.1.9 CARCINOGENICITY 88
8.1.10 NEUROTOXICITY 89
8.1.11 OTHER TOXICITY ENDPOINTS & TESTS 91
9 IN VITRO TOXICOLOGY TESTING MARKET, BY TECHNOLOGY 93
9.1 INTRODUCTION 94
9.2 CELL CULTURE TECHNOLOGIES 95
9.3 HIGH-THROUGHPUT TECHNOLOGIES 97
9.4 CELLULAR IMAGING TECHNOLOGIES 99
9.5 TOXICOGENOMICS 101
10 IN VITRO TOXICOLOGY TESTING MARKET, BY INDUSTRY 103
10.1 INTRODUCTION 104
10.2 PHARMACEUTICAL AND BIOPHARMACEUTICAL INDUSTRY 105
10.3 COSMETICS AND HOUSEHOLD PRODUCTS INDUSTRY 107
10.4 FOOD INDUSTRY 109
10.5 CHEMICAL INDUSTRY 111
11 IN VITRO TOXICOLOGY TESTING MARKET, BY METHOD 113
11.1 INTRODUCTION 114
11.2 CELLULAR ASSAYS 114
11.3 BIOCHEMICAL ASSAYS 116
11.4 EX VIVO MODELS 117
12 IN VITRO TOXICOLOGY TESTING MARKET, BY REGION 118
12.1 INTRODUCTION 119
12.2 EUROPE 121
12.2.1 GERMANY 126
12.2.2 UK 130
12.2.3 FRANCE 135
12.2.4 ITALY 139
12.2.5 SPAIN 142
12.2.6 REST OF EUROPE (ROE) 146
12.3 NORTH AMERICA 150
12.3.1 US 154
12.3.2 CANADA 158
 
12.4 ASIA PACIFIC 162
12.4.1 JAPAN 167
12.4.2 CHINA 171
12.4.3 INDIA 175
12.4.4 REST OF ASIA PACIFIC (ROAPAC) 178
12.5 REST OF THE WORLD (ROW) 183
13 COMPETITIVE LANDSCAPE 187
13.1 OVERVIEW 187
13.2 MARKET RANKING ANALYSIS 187
14 COMPANY PROFILES 188
(Overview, Products and Services, Financials, Strategy & Development)*

14.1 SGS S.A. 188
14.2 COVANCE, INC. (A PART OF LABORATORY CORPORATION OF AMERICA HOLDINGS) 193
14.3 BIO-RAD LABORATORIES, INC. 197
14.4 QIAGEN N.V. 201
14.5 GE HEALTHCARE 205
14.6 EUROFINS SCIENTIFIC SE 208
14.7 MERCK KGAA 214
14.8 THERMO FISHER SCIENTIFIC, INC 218
14.9 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 223
14.10 CATALENT, INC. 226
14.11 CYPROTEX PLC (A SUBSIDIARY OF EVOTEC AG) 229
14.12 PROMEGA CORPORATION 234
14.13 GENTRONIX LIMITED 237
14.14 ASCENDANCE BIOTECHNOLOGY, INC. 239
14.15 MB RESEARCH LABORATORIES 242

*Details on Overview, Products and Services, Financials, Strategy & Development might not be Captured in case of Unlisted Companies.
15 APPENDIX 244
15.1 INSIGHTS OF INDUSTRY EXPERTS 244
15.2 DISCUSSION GUIDE 245
15.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 248
15.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 250
15.5 RELATED REPORTS 252
15.6 AUTHOR DETAILS 253